LAUSANNE, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London, UK, taking place April 7 – 9, 2019.
Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA will present an update on AC Immune’s broad clinical and preclinical pipeline of therapeutic and diagnostic candidates to treat neurodegenerative diseases associated with misfolded proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials and has collaborations with major pharmaceutical companies including Roche/Genentech, Eli Lilly and Janssen.
AC Immune utilizes two proprietary discovery platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases. These platforms have been validated through collaborations with major pharmaceutical companies, most recently a transformative agreement with Lilly for Tau Morphomer™ small molecules in Alzheimer’s disease and other Tau-related neurodegenerative diseases, with a total deal value of approx. CHF 1.8 billion.
H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2019 | 1:30 – 1:50pm BST
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune
A webcast of the presentation will be available on the Investor Page of AC Immune's investor page and at the H.C. Wainwright Global Life Sciences Conferencewebsite.
About AC Immune
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neuro-degenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.
For further information, please contact:
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Source: AC Immune SA